H. Ç. Yıldırım Et Al. , "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study," International Journal of Clinical Oncology , vol.29, no.3, pp.258-265, 2024
Yıldırım, H. Ç. Et Al. 2024. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. International Journal of Clinical Oncology , vol.29, no.3 , 258-265.
Yıldırım, H. Ç., KUTLU, Y., Mutlu, E., Aykan, M. B., Korkmaz, M., Yalçın, S., ... Şakalar, T.(2024). The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. International Journal of Clinical Oncology , vol.29, no.3, 258-265.
Yıldırım, Hasan Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study," International Journal of Clinical Oncology , vol.29, no.3, 258-265, 2024
Yıldırım, Hasan Ç. Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study." International Journal of Clinical Oncology , vol.29, no.3, pp.258-265, 2024
Yıldırım, H. Ç. Et Al. (2024) . "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study." International Journal of Clinical Oncology , vol.29, no.3, pp.258-265.
@article{article, author={Hasan Çağrı Yıldırım Et Al. }, title={The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study}, journal={International Journal of Clinical Oncology}, year=2024, pages={258-265} }